. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: J Thorac Cardiovasc Surg. 2021 Dec 23;164(2):389–397.e7. doi: 10.1016/j.jtcvs.2021.12.030

Table 2.

Comparison of clinical outcomes by treatment group

Characteristic	Full (N=453)	Abbreviated (N=364)	ICI (N=46)	Unknown (N=138)	P value^a
LOS	5.0 (4.0-7.0)	6.0 (4.0-8.0)	4.0 (3.0-5.8)	5.5 (4.0-8.0)	<0.001
Respiratory complication	77 (17)	66 (18)	11 (24)	26 (19)	0.7
In-hospital complication	160 (35)	131 (36)	19 (41)	49 (36)	0.9
Major complication^b	37 (8.2)	31 (8.5)	6 (13)	7 (5.1)	0.3
30-day mortality	8 (1.8)	8 (2.2)	1 (2.2)	1 (0.7)	0.7

Data are median (interquartile range) or no. (%). ICI, immune checkpoint inhibitor; LOS, length of stay.

Statistical tests performed: Kruskal-Wallis test; Pearson’s Chi-squared test of independence.

Major complications: Clavien-Dindo grade ≥3.^2,3